Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada Plans To Force Firms To Disclose Confidential Pricing Deals

Executive Summary

Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.

You may also be interested in...



Some Drug Prices Could Drop 40% Under Canada’s Cost Lowering Proposals

The prices of patented medicines overall are expected to go down in Canada under new proposed regulatory amendments.

Hep C And Other High-Cost Drugs Behind 10% Rise In Canadian Medicines Spend

Public drug plan spending on medicines in Canada rose by nearly 10% in 2015-16, driven by a shift to the use of expensive patented drugs such as the direct acting antivirals for hepatitis C.

Canada Plans Drug Price Reductions By Changing Reference Country List

Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.

Related Content

Topics

UsernamePublicRestriction

Register

PS120768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel